Merck & Co., Inc. MRK
At closeNov 13, 2026, 7:41 PM EST
After hours · Nov 13, 7:41 PM ET
- YTD
- +40.38%
- 1 year
- +59.00%
- Market cap
- 364.26B
- Revenue (ttm)
- 67.38B
- Profit margin
- 3.64%
- EPS (ttm)
- 0.99
- Shares out
- 2.47B
- P/E ratio
- 149.25
- Forward P/E
- 16.45
- Dividend
- 3.40 (2.31%)
- Ex-dividend date
- Sep 14, 2026
- YTD return
- +40.38%
- 1-year return
- +59.00%
- Volume
- 6.51M
- Avg volume
- 10.21M
- Open
- 147.31
- Previous close
- 146.95
- Day's range
- 145.24 – 147.99
- 52-week range
- 91.49 – 156.92
- Beta
- 0.12
- Analysts
- Buy
- Price target
- 161.53 (+9.3%)
- Earnings date
- Feb 2, 2027
5D +0.37 (+0.25%)
Key statistics
- Enterprise value
- 406.57B
- PEG ratio
- 3.56
- Price / sales
- 5.41
- Price / book
- 8.12
- Dividend yield
- 2.31%
- Payout ratio
- 343.43%
- Revenue growth
- 4.70%
- Free cash flow
- 14.02B
- Total cash
- 9.65B
- Total debt
- 53.90B
- Return on equity
- 5.06%
- Short % of float
- 1.08%
- 50-day average
- 146.22
- 200-day average
- 128.45
Analyst view
Consensus: buy
- Target (low)
- 105.00
- Target (mean)
- 161.53
- Target (high)
- 186.00
- Strong buy5
- Buy14
- Hold9
- Sell0
- Strong sell0
Next earnings
Feb 2, 2027
Expected Feb 2, 2027. Consensus EPS estimate 1.76.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 2, 2027 | Dec 30, 2026 | 1.78 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 2.09 | 2.49 | +0.40 | +19.14% |
| Aug 4, 2026 | Jun 30, 2026 | -0.27049 | -0.13 | +0.14 | +51.94% |
| Apr 30, 2026 | Mar 31, 2026 | -1.47 | -1.28 | +0.19 | +12.93% |
| Feb 3, 2026 | Dec 31, 2025 | 2.01 | 2.04 | +0.03 | +1.49% |
| Oct 30, 2025 | Sep 30, 2025 | 2.36 | 2.58 | +0.22 | +9.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Freedom Broker | main | Hold | Hold |
| Nov 2, 2026 | Cantor Fitzgerald | main | Neutral | Neutral |
| Oct 30, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 30, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Oct 30, 2026 | Guggenheim | main | Buy | Buy |
| Oct 26, 2026 | Barclays | main | Overweight | Overweight |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- merck.com
News
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season 
EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Merck’s WELIREG Plus Lenvatinib For Treatment Of Advanced Renal Cell Carcinoma With Clear Cell Component; Final Decision Expected In Next Two Months 
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy 
FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report 
3 Pharmaceutical Stocks That Offer Safety and Growth 
What Merck KGaA (MRK) Said on Its Q3 Earnings Call 
Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities 
Merck to Participate in the Jefferies Global Healthcare Conference in London 
Want a Dividend Check Every Month? This Dividend ETF Paid You 12 Times in the Past Year 
Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year
Your note
Sign in to keep a note on MRK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHATTOPADHYAY SANAT | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 200,675 |
| DAVIS ROBERT M | Chief Executive Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 450,351 |
| DELUCA RICHARD ROBERT JR. | Officer | Sale | Aug 11, 2026 | 110,167 |
| GUINDO CHIRFI | Officer | Sale | Aug 12, 2026 | 36,613 |
| LI DEAN Y | Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 94,431 |
| LITCHFIELD CAROLINE | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 28, 2026 | 92,300 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.21% | 226,999,837 | 33.55B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.54% | 161,323,174 | 23.84B | Jun 29, 2026 |
| State Street Corporation | 4.93% | 121,422,392 | 17.94B | Sep 29, 2026 |
| Wellington Management Group, LLP | 3.50% | 86,249,283 | 12.75B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.75% | 67,738,969 | 10.01B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.50% | 61,565,702 | 9.10B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18% | 78,411,374 | 11.59B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.60% | 63,996,884 | 9.46B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 1.47% | 36,188,606 | 5.35B | Aug 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 32,874,367 | 4.86B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 32,063,279 | 4.74B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 30,514,312 | 4.51B | Sep 29, 2026 |